Findings

What do systematic reviews say?

11 questions · 11 findings · 3 reviews · Dementia and Cognitive Improvement

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 9.1%Low 4 · 36.4%Moderate 5 · 45.5%High 1 · 9.1%

Discontinuing cholinesterase inhibitor vs continued cholinesterase inhibitor

Adverse events (any) · people with dementia

Discontinuing cholinesterase inhibitor showed no clear difference in adverse events (any) compared with continued cholinesterase inhibitor (low certainty).

1 finding from 1 review

Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia 2021 · Cochrane Headline outcomes only
OR 0.85 [0.57, 1.27]
4 studies · 446 participants
Low

Discontinuing cholinesterase inhibitor vs continued cholinesterase inhibitor

SAEs · people with dementia

Discontinuing cholinesterase inhibitor showed no clear difference in serious adverse events (SAEs) compared with continued cholinesterase inhibitor (low certainty).

1 finding from 1 review

Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia 2021 · Cochrane Headline outcomes only
OR 0.8 [0.46, 1.39]
4 studies · 390 participants
Low

Rivastigmine vs placebo

Adverse events: nausea · people with delirium

Cholinesterase inhibitors (rivastigmine) showed no clear difference in adverse events nausea compared with placebo (low certainty).

1 finding from 1 review

Cholinesterase inhibitors for the treatment of delirium in non‐ICU settings 2018 · Cochrane Headline outcomes only
RR 0.3 [0.01, 6.29]
1 study · 15 participants
Low

Galantamine vs placebo

Adverse events (all adverse events) at 26 weeks · vascular dementia and other vascular cognitive impairments

Galantamine probably leads to higher adverse events (all adverse events) at 26 weeks compared with placebo (moderate certainty).

1 finding from 1 review

Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
OR 1.57 [1.02, 2.43]
2 studies · 1378 participants
Moderate

Donepezil 10 mg/day vs placebo

Adverse events (all adverse events) at 24 weeks · vascular dementia and other vascular cognitive impairments

Donepezil 10 mg leads to higher adverse events (all adverse events) at 24 weeks compared with placebo (high certainty).

1 finding from 1 review

Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
OR 1.95 [1.2, 3.15]
2 studies · 813 participants
High

Donepezil 10 mg/day vs placebo

Serious adverse events (excluding death) at 24 weeks · vascular dementia and other vascular cognitive impairments

Donepezil 10 mg showed no clear difference in serious adverse events (excluding death) at 24 weeks compared with placebo (moderate certainty).

1 finding from 1 review

Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
OR 1.15 [0.81, 1.64]
2 studies · 813 participants
Moderate

Donepezil 5 mg vs placebo

Serious adverse events (excluding death) at 24 weeks · vascular dementia and other vascular cognitive impairments

Donepezil 5 mg showed no clear difference in serious adverse events (excluding death) at 24 weeks compared with placebo (moderate certainty).

1 finding from 1 review

Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
OR 0.94 [0.72, 1.22]
3 studies · 1772 participants
Moderate

Rivastigmine vs placebo

Adverse events (all adverse events) at 24 to 26 weeks · vascular dementia and other vascular cognitive impairments

It is very uncertain whether rivastigmine changes adverse events (all adverse events) at 24 to 26 weeks compared with placebo (very low certainty).

1 finding from 1 review

Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
OR 3.21 [0.36, 28.88]
3 studies · 831 participants
Very low

Galantamine vs placebo

Serious adverse events (excluding deaths) at 26 weeks · vascular dementia and other vascular cognitive impairments

Galantamine showed no clear difference in serious adverse events (excluding deaths) at 26 weeks compared with placebo (moderate certainty).

1 finding from 1 review

Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
OR 1.12 [0.78, 1.59]
1 study · 786 participants
Moderate

Rivastigmine vs placebo

Serious adverse events (excluding death) at 24 to 26 weeks · vascular dementia and other vascular cognitive impairments

Rivastigmine showed no clear difference in serious adverse events (excluding death) at 24 to 26 weeks compared with placebo (low certainty).

1 finding from 1 review

Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
OR 1.42 [0.9, 2.25]
2 studies · 622 participants
Low

Donepezil 5 mg vs placebo

Adverse events (all reported adverse events grouped) at 24 weeks · vascular dementia and other vascular cognitive impairments

Donepezil 5 mg showed no clear difference in adverse events (all reported adverse events grouped) at 24 weeks compared with placebo (moderate certainty).

1 finding from 1 review

Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
OR 1.22 [0.94, 1.58]
3 studies · 1772 participants
Moderate